FINHUB Insights

EW · Q1 FY26 · Mar 31, 2026

Edwards Lifesciences Q1 FY26: where the revenue came from and where it went

Edwards Lifesciences Q1 FY26: revenue $1.6B (+17% year over year). Net profit $0.4B. Largest cohort Transcatheter Aortic Valve… $1.2B. The whole income statement as a sankey diagram from the SEC filing.

Period
Mar 31, 2026
Reported
May 6, 2026 10-Q
Sankey diagram of Edwards Lifesciences's income statement for Q1 FY26: revenue of $1.6 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$1.6B +17% year over year
Gross profit$1.3B 78% margin
Operating profit$0.5B 29% margin
Net profit$0.4B 23% margin

The numbers

All figures in billions of U.S. dollars, for Q1 FY26 (period ends Mar 31, 2026).
ItemValueShare of revenueYear over year
Revenue 1.6 100% +17%
Transcatheter Aortic Valve… 1.2 75% +14%
Surgical 0.3 19% +10%
Transcatheter Mitral and… 0.2 12% +52%
Cost of revenue−0.425%
Gross profit1.378% margin−1pp
Research & development−0.316%−2pp
SG&A−0.532%−1pp
Operating profit0.529% margin+1pp
Tax−0.1
Net profit0.423%−2pp
Filing on EDGAR More quarters of EW

Source of the numbers: structured XBRL data from the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters